Cargando…
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466559/ https://www.ncbi.nlm.nih.gov/pubmed/34577823 http://dx.doi.org/10.3390/medicina57090900 |
_version_ | 1784573172069171200 |
---|---|
author | Del Giudice, Maria Livia Gozzetti, Alessandro Antonioli, Elisabetta Orciuolo, Enrico Ghio, Francesco Ciofini, Sara Candi, Veronica Fontanelli, Giulia Attucci, Irene Formica, Giuseppe Bocchia, Monica Galimberti, Sara Petrini, Mario Buda, Gabriele |
author_facet | Del Giudice, Maria Livia Gozzetti, Alessandro Antonioli, Elisabetta Orciuolo, Enrico Ghio, Francesco Ciofini, Sara Candi, Veronica Fontanelli, Giulia Attucci, Irene Formica, Giuseppe Bocchia, Monica Galimberti, Sara Petrini, Mario Buda, Gabriele |
author_sort | Del Giudice, Maria Livia |
collection | PubMed |
description | Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy. |
format | Online Article Text |
id | pubmed-8466559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84665592021-09-27 Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study Del Giudice, Maria Livia Gozzetti, Alessandro Antonioli, Elisabetta Orciuolo, Enrico Ghio, Francesco Ciofini, Sara Candi, Veronica Fontanelli, Giulia Attucci, Irene Formica, Giuseppe Bocchia, Monica Galimberti, Sara Petrini, Mario Buda, Gabriele Medicina (Kaunas) Article Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy. MDPI 2021-08-28 /pmc/articles/PMC8466559/ /pubmed/34577823 http://dx.doi.org/10.3390/medicina57090900 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Del Giudice, Maria Livia Gozzetti, Alessandro Antonioli, Elisabetta Orciuolo, Enrico Ghio, Francesco Ciofini, Sara Candi, Veronica Fontanelli, Giulia Attucci, Irene Formica, Giuseppe Bocchia, Monica Galimberti, Sara Petrini, Mario Buda, Gabriele Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title_full | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title_fullStr | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title_full_unstemmed | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title_short | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study |
title_sort | real-life experience with pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma: a retrospective and prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466559/ https://www.ncbi.nlm.nih.gov/pubmed/34577823 http://dx.doi.org/10.3390/medicina57090900 |
work_keys_str_mv | AT delgiudicemarialivia reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT gozzettialessandro reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT antoniolielisabetta reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT orciuoloenrico reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT ghiofrancesco reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT ciofinisara reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT candiveronica reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT fontanelligiulia reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT attucciirene reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT formicagiuseppe reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT bocchiamonica reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT galimbertisara reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT petrinimario reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy AT budagabriele reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy |